Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NPM1 - ALK ALK G1269A||Advanced Solid Tumor||conflicting||Ceritinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).||27009859|
|NPM1 - ALK ALK G1269A||Advanced Solid Tumor||conflicting||Ceritinib||Preclinical - Cell culture||Actionable||In a preclinical study, Zykadia (ceritinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).||25727400|
|PubMed Id||Reference Title||Details|
|(25727400)||Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.||Full reference...|
|(27009859)||TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.||Full reference...|